GSK Inks $2 Billion For Cough Medicine Biotech To Bolster Drug ... - Forbes
WEBApr 18, 2023 · Pharma giant GlaxoSmithKline on Tuesday announced a deal to buy Canadian biotech Bellus Health for $2 billion, betting big on the firm’s cough medicine as it moves to shore up its slender drug...
GSK bets on cough drug with $2bn deal for Canadian biotech
WEBApr 18, 2023 · The deal is designed to bolster GSK’s drug pipeline by adding Bellus Health’s speciality medicine for a debilitating and persistent cough, a condition that GSK says affects 10mn people.
GSK to buy Bellus Health and its chronic cough drug for $2B
WEBApr 18, 2023 · GSK on Tuesday said it will pay $2 billion to acquire Bellus Health, a Canada-based developer of an experimental drug for chronic cough that’s in late-stage clinical trials. Deal terms value each Bellus share at $14.75, roughly double their closing price on Monday.
GSK to Buy Bellus for $2 Billion to Gain Cough Medicine
WEBApr 18, 2023 · GSK Plc agreed to buy Canadian biotech Bellus Health Inc. for about $2 billion to bolster its pipeline of experimental medicines.
GSK to Gain Chronic Cough Drug With $2B Buyout of Bellus Health
WEBApr 18, 2023 · Acquiring Bellus Health gives GSK a drug for recurrent chronic cough that could offer a better side effect profile compared to a Merck drug that addresses the same target.
GSK bets $2 bln on Bellus cough drug to soothe pipeline fears
WEBApr 18, 2023 · GSK plans to buy Canada-based drug developer Bellus Health Inc in an all-cash deal for $2 billion as the British drugmaker expands its bet on respiratory therapies.
GSK to buy Bellus Health, gaining chronic cough drug - STAT
WEBApr 18, 2023 · With the Bellus Health acquisition, GSK will get the experimental drug camlipixant, which is in a Phase 3 trial for refractory chronic cough.
GSK bolsters respiratory pipeline with Bellus Health buy
WEBApr 18, 2023 · GSK has agreed to acquire Canada’s Bellus Health for around $2 billion, bolting on a late-stage drug candidate for chronic refractory cough. The $14.75-per-share deal will add P2X3 antagonist...
GSK buys purine receptor antagonist for $2 billion - Nature
WEBMay 10, 2023 · GSK has acquired BELLUS Health to secure rights to camlipixant, signalling continued interest in P2X purinoceptor 3 (P2X3) antagonists for refractory chronic cough.
GSK To Buy Cough Medicine Biotech Bellus Health For $2B
WEBPharma giant GlaxoSmithKline on Tuesday announced a deal to buy Canadian biotech Bellus Health for $2 billion, betting big on the firm’s cough medicine as it moves to shore up its slender drug pipeline ahead of the expected loss of …